OBJECTIVE: To evaluate the efficacy of methylphenidate in treating adults with attention-deficit hyperactivity disorder (ADHD), using subjective (self-report) and objective (computerized test) measures. METHOD: This double-blind crossover trial of placebo vs methylphenidate included subjects with childhood and current ADHD symptoms, IQs above 80, no other psychiatric condition explaining their difficulties or requiring other treatment, and no substance abuse in the previous 6 months. We administered 10 mg 3 times daily of medication (that is, placebo or methylphenidate) for 2 weeks. On the final day, subjects completed self-report measures and were tested on computerized tests. We then increased dosage to 15 mg 3 times daily for 2 weeks and administered a complete reassessment on the final day. Following a 1-week washout, we repeated this process on the second medication (that is, placebo or methylphenidate). RESULTS:Thirty adults with ADHD participated. Self-report measures and computerized tests showed significant improvements in ADHD symptoms on methylphenidate, compared with placebo. Other psychiatric symptoms (notably, anxiety and depression) were alleviated with methylphenidate. There was no significant difference between the 2 dosages of methylphenidate. CONCLUSION:Methylphenidate is effective in improving ADHD symptoms in adults with ADHD, is well tolerated, and has minimal side effects.
RCT Entities:
OBJECTIVE: To evaluate the efficacy of methylphenidate in treating adults with attention-deficit hyperactivity disorder (ADHD), using subjective (self-report) and objective (computerized test) measures. METHOD: This double-blind crossover trial of placebo vs methylphenidate included subjects with childhood and current ADHD symptoms, IQs above 80, no other psychiatric condition explaining their difficulties or requiring other treatment, and no substance abuse in the previous 6 months. We administered 10 mg 3 times daily of medication (that is, placebo or methylphenidate) for 2 weeks. On the final day, subjects completed self-report measures and were tested on computerized tests. We then increased dosage to 15 mg 3 times daily for 2 weeks and administered a complete reassessment on the final day. Following a 1-week washout, we repeated this process on the second medication (that is, placebo or methylphenidate). RESULTS: Thirty adults with ADHD participated. Self-report measures and computerized tests showed significant improvements in ADHD symptoms on methylphenidate, compared with placebo. Other psychiatric symptoms (notably, anxiety and depression) were alleviated with methylphenidate. There was no significant difference between the 2 dosages of methylphenidate. CONCLUSION:Methylphenidate is effective in improving ADHD symptoms in adults with ADHD, is well tolerated, and has minimal side effects.
Authors: Erin S Calipari; Mark J Ferris; James R Melchior; Kristel Bermejo; Ali Salahpour; David C S Roberts; Sara R Jones Journal: Addict Biol Date: 2012-03-28 Impact factor: 4.280
Authors: Connor Martin; Dennis Fricke; Abisha Vijayashanthar; Courtney Lowinger; Dimitris Koutsomitis; Daniel Popoola; Michael Hadjiargyrou; David E Komatsu; Panayotis K Thanos Journal: Pharmacol Biochem Behav Date: 2018-07-18 Impact factor: 3.533
Authors: Emily Carias; Dennis Fricke; Abisha Vijayashanthar; Lauren Smith; Rathini Somanesan; Connor Martin; Leanna Kalinowski; Daniel Popoola; Michael Hadjiargyrou; David E Komatsu; Panayotis K Thanos Journal: Behav Brain Res Date: 2018-08-24 Impact factor: 3.332
Authors: Panayotis K Thanos; Lisa S Robison; Jessica Steier; Yu Fen Hwang; Thomas Cooper; James M Swanson; David E Komatsu; Michael Hadjiargyrou; Nora D Volkow Journal: Pharmacol Biochem Behav Date: 2015-01-29 Impact factor: 3.533
Authors: Sandra J J Kooij; Susanne Bejerot; Andrew Blackwell; Herve Caci; Miquel Casas-Brugué; Pieter J Carpentier; Dan Edvinsson; John Fayyad; Karin Foeken; Michael Fitzgerald; Veronique Gaillac; Ylva Ginsberg; Chantal Henry; Johanna Krause; Michael B Lensing; Iris Manor; Helmut Niederhofer; Carlos Nunes-Filipe; Martin D Ohlmeier; Pierre Oswald; Stefano Pallanti; Artemios Pehlivanidis; Josep A Ramos-Quiroga; Maria Rastam; Doris Ryffel-Rawak; Steven Stes; Philip Asherson Journal: BMC Psychiatry Date: 2010-09-03 Impact factor: 3.630